Founded in 1999, toXcel is committed to promoting and improving the safety, health, and well-being of people everywhere. We work with businesses, government agencies and communities to offer reliable scientific, analytic, technical, and regulatory services.
Headquartered in the Metropolitan Washington, DC region, with offices located across the U.S. and in the United Kingdom, toXcel brings worldwide expertise to challenging scientific issues in toxicology, environment, transportation, public health, and other domains.
toXcel is pleased to announce the recent addition of Dr. Raluca Kubaszky to our Life Sciences team!
Raluca Kubaszky, DVM, PhD, DABT joins the toXcel Life Sciences team as Executive Director of Nonclinical Development. Raluca is a veterinarian by training and a board-certified toxicologist, with over 20 years of CRO and academic experience in nonclinical study design and management of complex projects. She obtained a doctorate in Veterinary Medicine from the Faculty of Veterinary Medicine, University of Agronomical Sciences Bucharest, Romania and later specialized in nonclinical research after completing a Ph.D. in Veterinary Medicine, Endocrinology of Reproduction. She is a Diplomate of the American Board of Toxicology since 2011.
In her new position with toXcel, Raluca has taken a leadership role in the expansion of our pharmaceutical, biotechnology and radiation safety services within our corporate global portfolio. She will also provide key support to our major chemical/agrochemical projects and implementation of toXcel’s presence in Canada, in addition to the extension of services provided in our US and European-based offices. Dr. Kubaszky has nonclinical experience with cell and gene therapies, biologic, biosimilar, and small-molecule products for a wide variety of indications, as well as multiple routes of administration (e.g., oral, intravenous, subcutaneous, intra-articular, intranasal, intravesicular or dermal) and special expertise in radiation safety programs.
The Latest QSAR Capabilities
toXcel is pleased to announce that we now have a contract with Leadscope Inc. which enables us to offer a number of QSAR Toxicity Prediction models including impurity assessment according to ICH M7. Please reach out to Christine McAlinden for details.
in vitro Toxicology Updates
Chris McAlinden participated in the ‘Applied in vitro toxicology course’ jointly organised by the European Society of Toxicology In Vitro (ESTIV) and the American Society for Cellular and Computational Toxicology (ASCCT) – the course covered subjects pertinent to current regulatory, screening and investigative in vitro toxicology issues, as well as practical laboratory examples. This experience will contribute to the guidance we are able to provide for our clients regarding the use and acceptance of in vitro methods for investigative and regulatory purposes.